BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20515869)

  • 1. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.
    Schroth W; Hamann U; Fasching PA; Dauser S; Winter S; Eichelbaum M; Schwab M; Brauch H
    Clin Cancer Res; 2010 Sep; 16(17):4468-77. PubMed ID: 20515869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
    Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
    Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
    Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
    J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
    Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
    Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ethics of CYP2D6 testing for patients considering tamoxifen.
    Hartman AR; Helft P
    Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
    Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
    Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.
    Kiyotani K; Mushiroda T; Hosono N; Tsunoda T; Kubo M; Aki F; Okazaki Y; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    Pharmacogenet Genomics; 2010 Sep; 20(9):565-8. PubMed ID: 20574415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.
    Ramón y Cajal T; Altés A; Paré L; del Rio E; Alonso C; Barnadas A; Baiget M
    Breast Cancer Res Treat; 2010 Jan; 119(1):33-8. PubMed ID: 19189210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
    Peppercorn J; A Carey L
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):191-4. PubMed ID: 18279059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
    Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
    Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
    Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
    Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
    Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
    Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 genotype and tamoxifen response.
    Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
    Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
    [No Abstract]   [Full Text] [Related]  

  • 19. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
    Newman WG; Hadfield KD; Latif A; Roberts SA; Shenton A; McHague C; Lalloo F; Howell S; Evans DG
    Clin Cancer Res; 2008 Sep; 14(18):5913-8. PubMed ID: 18794105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized tamoxifen: a step closer but miles to go.
    Bardia A; Stearns V
    Clin Cancer Res; 2010 Sep; 16(17):4308-10. PubMed ID: 20651057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.